Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia

Moazzami, Kasra; Majdzadeh, Reza

doi:10.1002/14651858.cd008347.pub2

Cited by 20 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These correlations in our opinion are in accord to Asahara in vitro experiment and Li in vivo ischemic mouse model where CD34+ cells are involved in endothelial differentiation and reparative ischemic injury [27, 28]. Some researchers studied a possible role for CD34+ precursor cells in the therapy of critical lower limb ischemia CLI [29]. For example, in the Naples study, intra-arterial injected CD34+ cells of bone marrow origin were sufficient to significantly reduce time-free amputation time in a mixed diabetic and atherosclerotic ischemic group where Rutherford category 6 was exclusion criteria [30].…”

Section: Discussionsupporting

confidence: 79%

Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot

Sambataro

Seganfreddo

Canal

et al. 2014

International Journal of Vascular Medicine

View full text Add to dashboard Cite

Objective. We studied circulating precursor cells (CPC) in type 2 diabetes mellitus (T2DM) with neuropathic foot lesions with or without critical limb ischemia and relationships between endothelial precursor cells (EPC) and peripheral neuropathy. Methods and Subjects. We measured peripheral blood CD34, CD133, and CD45 markers for CPC and KDR, CD31 markers for EPC by citofluorimetry and systemic neural nociceptor CGRP (calcitonin gene related protein) by ELISA in 8 healthy controls (C) and 62 T2DM patients: 14 with neuropathy (N), 20 with neuropathic foot lesions (N1), and 28 with neuroischemic recent revascularized (N2) foot lesions. Timing of lesions was: acute (until 6 weeks), healed, and not healed. Results. CD34+ and CD133+ were reduced in N, N1, and N2 versus C, and CD34+ were lower in N2 versus N1 (P = 0.03). In N2 CD34+KDR+ remain elevated in healed versus chronic lesions and, in N1 CD133+31+ were elevated in acute lesions. CGRP was reduced in N2 and N1 versus C (P < 0.04 versus C 26 ± 2 pg/mL). CD34+KDR+ correlated in N2 with oximetry and negatively in N1 with CGRP. Conclusions. CD34+ CPC are reduced in diabetes with advanced complications and diabetic foot. CD34+KDR+ and CD31+133+ EPC differentiation could have a prognostic and therapeutic significance in the healing process of neuropathic and neuroischemic lesions.

show abstract

Section: Discussionsupporting

confidence: 79%

Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot

Sambataro

Seganfreddo

Canal

et al. 2014

International Journal of Vascular Medicine

View full text Add to dashboard Cite

show abstract

“…However, aging is also associated with deficits in the regulatory networks of mesenchymal stromal cells, underscoring the complexity of interventions to enhance angiogenesis in aged tissues (Lepperdinger, 2011). Subsequent clinical trials have been slow to evolve due to insufficient data showing consistent benefit (Moazzami et al, 2011), and concerns that activation of this cascade could promote neoplastic processes (Quante et al, 2011). …”

Section: D Stem Cells and Extracellular Matrixmentioning

confidence: 99%

The effect of aging on the cutaneous microvasculature

Bentov

Reed

2015

Microvascular Research

View full text Add to dashboard Cite

Aging is associated with a progressive loss of function in all organs. Under normal conditions the physiologic compensation for age-related deficits is sufficient, but during times of stress the limitations of this reserve become evident. Explanations for this reduction in reserve include the changes in the microcirculation that occur during the normal aging process. The microcirculation is defined as the blood flow through arterioles, capillaries and venules, which are the smallest vessels in the vasculature and are embedded within organs and tissues. Optimal strategies to maintain the microvasculature following surgery and other stressors must use multifactorial approaches. Using skin as the model organ, we will review the anatomical and functional changes in the microcirculation with aging, and some of the available clinical strategies to potentially mitigate the effect of these changes on important clinical outcomes.

show abstract

“…159 The effect of in vivo flow conditions on EPCs has been studied in vitro and is shown to influence EPC alignment and adhesion molecule expression consistent with the endothelial phenotype. 160,161 …”

Section: Clinical Stem Cell Studies In Peripheral Vascular Diseasementioning

confidence: 99%

Cell Therapy of Peripheral Arterial Disease

Raval

Losordo

2013

Circulation Research

197

View full text Add to dashboard Cite

The age-adjusted prevalence of peripheral arterial disease in the US population was estimated to approach 12% in 1985, and as the population ages, the overall population having peripheral arterial disease is predicted to rise. The clinical consequences of occlusive peripheral arterial disease include intermittent claudication, that is, pain with walking, and critical limb ischemia (CLI), which includes pain at rest and loss of tissue integrity in the distal limbs, which may ultimately lead to amputation of a portion of the lower extremity. The risk factors for CLI are similar to those linked to coronary artery disease and include advanced age, smoking, diabetes mellitus, hyperlipidemia, and hypertension. The worldwide incidence of CLI was estimated to be 500 to 1000 cases per million people per year in 1991. The prognosis is poor for CLI subjects with advanced limb disease. One study of >400 such subjects in the United Kingdom found that 25% required amputation and 20% (including some subjects who had required amputation) died within 1 year. In the United States, ≈280 lower-limb amputations for ischemic disease are performed per million people each year. The first objective in treating CLI is to increase blood circulation to the affected limb. Theoretically, increased blood flow could be achieved by increasing the number of vessels that supply the ischemic tissue with blood. The use of pharmacological agents to induce new blood vessel growth for the treatment or prevention of pathological clinical conditions has been called therapeutic angiogenesis. Since the identification of the endothelial progenitor cell in 1997 by Asahara and Isner, the field of cell-based therapies for peripheral arterial disease has been in a state of continuous evolution. Here, we review the current state of that field.

show abstract

Local intramuscular transplantation of autologous mononuclear cells for critical lower limb ischaemia

Cited by 20 publications

References 24 publications

Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot

Prognostic Significance of Circulating and Endothelial Progenitor Cell Markers in Type 2 Diabetic Foot

The effect of aging on the cutaneous microvasculature

Cell Therapy of Peripheral Arterial Disease

Contact Info

Product

Resources

About